Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 8/20 | 0.71 |
| ▸ | MCHR1 | Q99705 | 7/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.56 |
| ▸ | CCR2 | P41597 | 4/20 | 0.56 |
| ▸ | ITK | Q08881 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659975 | 0.83 | ROCK2 (1.00) | ROCK2ROCK1CCR2ITK | |
| SCHEMBL12846292 | 0.79 | ROCK2 (0.56) | ROCK2MCHR1ROCK1CCR2 | |
| SCHEMBL659088 | 0.78 | ROCK2 (0.80) | ROCK2ROCK1CCR2ITK | |
| SCHEMBL19500904 | 0.76 | MCHR1 (0.77) | ROCK2MCHR1ROCK1CCR2 | |
| SCHEMBL12846293 | 0.75 | MCHR1 (0.56) | ROCK2MCHR1ROCK1CCR2 | |
| SCHEMBL5870954 | 0.74 | ROCK2 (0.65) | ROCK2ROCK1CCR2 | |
| SCHEMBL32679933 | 0.72 | KAT2B (0.54) | ROCK2ROCK1CCR2 | |
| SCHEMBL659846 | 0.71 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL2804629 | 0.71 | ROCK2 (1.00) | ROCK2ROCK1CCR2 | |
| SCHEMBL659847 | 0.71 | ROCK2 (1.00) | ROCK2ROCK1CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325959-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | INSPIRE PHARMACEUTICALS, INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325959-A1 | METHOD FOR TREATING OPHTHALMIC DISEASES USING RHO KINASE INHIBITOR COMPOUNDS | ROCK2, ROCK1, CIT | ROCK2 1/4885MCHR1 1483/4885ROCK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.